Liver Metastasis Colon Cancer Clinical Trial
Official title:
Immune Response to Irreversible Electroporation (NanoKnife ®) and a Checkpoint Inhibitor With or Without CpG Oligodeoxynucleotides for the Treatment of Stage IV Colorectal Cancer
The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis). The main questions it aims to answer are: 1. to document the rate of complications associated with combining IRE with immune boosting drugs. 2. After one liver metastasis is treated with IRE and immune boosting drugs, what is the change in the size of the non-IRE-treated liver metastases? 3. What is the immune response (measured in a blood sample) when IRE is combined with one or two types of immune boosting drugs?
Status | Not yet recruiting |
Enrollment | 12 |
Est. completion date | December 2027 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: 1. Biopsy-proven colorectal liver metastases with at least one measuring < 3.5 cm in diameter and accessible to percutaneous IRE such that a complete ablation of the lesion is possible. 2. Prior resection of the colorectal cancer primary. 3. The imaging has been reviewed in multi-disciplinary Rounds and the colorectal liver metastases have been deemed unresectable. 4. Patient has undergone chemotherapy and has not converted to resectable disease. 5. Radiologic evidence of stable disease for at least two months on systemic therapy for colorectal cancer (may have had prior partial response or disease progression) 6. Microsattelite instability (MSI)-stable or mismatch-proficient tumors 7. Patient has HLA phenotype of Human Leukocyte Antigen (HLA) A1 or HLA A2. 8. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Size of the metastasis being treated with IRE > 3.2 cm or < 2 cm. 2. Size of any non-IRE-treated liver metastasis > 4 cm 3. Pregnancy 4. Major comorbid disease 5. Active autoimmune disease 6. Bone or brain or peritoneal metastases. 7. MSI High disease 8. Patients with cardiac arrhythmia other than rate controlled atrial fibrillation. 9. Metal implant that cannot be removed within 10 cm of the area to be treated. 10. Peritoneal disease. 11. Poor performance status 12. Cirrhosis |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Saskatchewan |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complications | Complications (Clavien-Dindo classification of complications) at 30 days. The Clavien-Dindo Classification of Complications involves assigning a numbered classification to each complication, from 1-5, with 1 being a complication without need for any intervention required to 5 which is death of the patient. (a higher number indicates a higher severity). This is a validated measure in use for over 25 years. | 30 days | |
Primary | Complications | Complications (Clavien-Dindo classification of complications) at 90 days. The Clavien-Dindo Classification of Complications involves assigning a numbered classification to each complication, from 1-5, with 1 being a complication without need for any intervention required to 5 which is death of the patient. (a higher number indicates a higher severity). This is a validated measure in use for over 25 years. | 90 days | |
Primary | Abscopal effect: percent change in non-treated colorectal liver metastasis. | Two radiologists (one diagnostic and the other interventional) will examine the scans of all patients. They will select a colorectal metastasis from the scan just before the intervention that is between 2-3.2 cm in maximal diameter, accessible to percutaneous ablation, and treatable according to the interventional radiologist's opinion. Another metastasis, with a maximal diameter of less than 4 cm, will be selected to monitor for the abscopal effect (reduction in size of a colorectal liver metastasis that was not treated with IRE). After 3 months, the radiologists will review the imaging again. They will assess the treatment mass area for any contrast uptake indicating incomplete ablation. The second metastasis will be measured in the same dimensions as before treatment. The difference in maximal diameter of the second metastasis will be calculated as (diameter before IRE - diameter after IRE) / diameter before IRE and expressed as a percentage. |
3 months from the time of IRE | |
Secondary | Tumor-specific immune response: distribution on flow-cytometry plot | Distribution of Carcinoembryonic (CEA)-specific CD8+ T cells, CD4+ T cells, type-1 and 2 macrophages (M1 and M2), regulatory T (Treg) cells on the flow-cytometry plot. | Day 8 | |
Secondary | Tumor-specific immune response: serum cytokine concentrations | Interleukin(IL)-2, Interferon (IFN)-a, IFN-?, IL-10 and Transforming Growth Factor (TGF)-ß. | Day 8 | |
Secondary | Tumor-specific immune response: distribution on flow-cytometry plot. | Distribution of Carcinoembryonic (CEA)-specific CD8+ T cells, CD4+ T cells, type-1 and 2 macrophages (M1 and M2), regulatory T (Treg) cells on the flow-cytometry plot. | Day 14 | |
Secondary | Tumor-specific immune response: serum cytokin concentrations | Interleukin(IL)-2, Interferon (IFN)-a, IFN-?, IL-10 and Transforming Growth Factor (TGF)-ß. | Day 14 | |
Secondary | Tumor-specific immune response: distribution on flow-cytometry plot. | Distribution of Carcinoembryonic (CEA)-specific CD8+ T cells, CD4+ T cells, type-1 and 2 | Day 30 | |
Secondary | Tumor-specific immune response | Interleukin(IL)-2, Interferon (IFN)-a, IFN-?, IL-10 and Transforming Growth Factor (TGF)-ß. | Day 30 | |
Secondary | Progression-free survival | Progression-free survival will be determined based on the CT scan conducted after one year. To prove the absence of progression, there should be no contrast uptake in the area that was treated with IRE one year prior, AND the maximal diameter of the second lesion (not treated with IRE) should have increased by less than 10%. | 1 year | |
Secondary | Progression-free survival | Progression-free survival will be determined based on the CT scan conducted after two years. To prove the absence of progression, there should be no contrast uptake in the area that was treated with IRE two years prior, AND the maximal diameter of the second lesion (not treated with IRE) should have increased by less than 10% | 2 years | |
Secondary | Quality of life questionnaire | Quality of life using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire, a 27-item questionnaire, each item to be rated 1-5. The scores are totalled and total scores range from 0-108, with higher scores indicating a higher quality of life. | baseline | |
Secondary | Quality of life questionnaire | Quality of life using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire, a 27-item questionnaire, each item to be rated 1-5. The scores are totalled and total scores range from 0-108, with higher scores indicating a higher quality of life. | 12 weeks | |
Secondary | Quality of life questionnaire | Quality of life using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire, a 27-item questionnaire, each item to be rated 1-5. The scores are totalled and total scores range from 0-108, with higher scores indicating a higher quality of life. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05775146 -
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
|
Phase 2 | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03562234 -
The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases
|
||
Recruiting |
NCT03732235 -
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
|
||
Recruiting |
NCT06126419 -
Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
|
N/A | |
Active, not recruiting |
NCT05616039 -
I-FIGS Feasibility Study
|
N/A | |
Withdrawn |
NCT05175092 -
Living Donor Liver Transplantation for CRC Liver Metastases
|
N/A | |
Recruiting |
NCT04798898 -
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
|
N/A | |
Not yet recruiting |
NCT06071052 -
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
|
N/A | |
Not yet recruiting |
NCT06053996 -
Hepatopulmonary Radio-sterilization With Immunotherapy
|
N/A | |
Recruiting |
NCT04491929 -
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
|
||
Not yet recruiting |
NCT06050200 -
TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
|
N/A | |
Enrolling by invitation |
NCT03444194 -
Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study
|
N/A | |
Not yet recruiting |
NCT05884723 -
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
|
N/A | |
Not yet recruiting |
NCT06185556 -
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
|
Phase 2/Phase 3 | |
Recruiting |
NCT05755672 -
On-treatment Biomarkers in Metastatic Colorectal Cancer for Life
|
||
Recruiting |
NCT04595266 -
Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease
|
Phase 2 | |
Recruiting |
NCT04701281 -
Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06200831 -
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
|
N/A | |
Active, not recruiting |
NCT04046445 -
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
|
Phase 1 |